Home Infusion Therapy Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Home Infusion Therapy Market 

5.1. COVID-19 Landscape: Home Infusion Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Home Infusion Therapy Market, By Product

8.1. Home Infusion Therapy Market, by Product, 2022-2030

8.1.1. Infusion Pumps

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Intravenous Sets

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. IV Cannulas

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Needleless Connectors

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Home Infusion Therapy Market, By Application

9.1. Home Infusion Therapy Market, by Application e, 2022-2030

9.1.1. Anti-infective

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Endocrinology

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Hydration Therapy

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Chemotherapy

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Enteral Nutrition

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.6. Parenteral Nutrition

9.1.6.1. Market Revenue and Forecast (2017-2030)

9.1.7. Specialty Pharmaceuticals

9.1.7.1. Market Revenue and Forecast (2017-2030)

9.1.8. Others

9.1.8.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Home Infusion Therapy Market, By Route of Administration 

10.1. Home Infusion Therapy Market, by Route of Administration, 2022-2030

10.1.1. Intramuscular

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Subcutaneously

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Epidural

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Home Infusion Therapy Market, By Route of Administration 

11.1. Home Infusion Therapy Market, by Route of Administration, 2022-2030

11.1.1. Patients

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Nurse

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Hospitals

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Home Infusion Therapy Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Product (2017-2030)

12.1.2. Market Revenue and Forecast, by Application (2017-2030)

12.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.1.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Product (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Product (2017-2030)

12.2.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Product (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Product (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Product (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Product (2017-2030)

12.3.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Product (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Product (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Product (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Product (2017-2030)

12.4.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Product (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Product (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Product (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Product (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

Chapter 13. Company Profiles

13.1. CVS/Coram

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Option Care Health

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. BriovaRx/Diplomat (UnitedHealth Optum)

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. PharMerica

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Fresenius Kabi

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. ICU Medical, Inc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. B. Braun Melsungen AG

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Baxter

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. BD

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Caesarea Medical Electronics

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms